Adults 30 to 70, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Latency During the Learning Phase of Virtual Morris Water Maze Test (vMWM)Primary· Baseline and 10 Weeks
Change from baseline of latency during the learning phase of vMWM (hidden platform training) in the neflamapimod first group compared to placebo first group
Group
Value
95% CI
Neflamapimod First
-6.92
± 3.814
Placebo First
-14.05
± 12.680
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 37 weeks. AEs occurring from when the subject signed the ICF until up to 30 days after the last dose were collected. Any AEs occurring before the start of treatment (i.e., before the first dose of the investigational product) were recorded in the medical history..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06815965 — A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
· Phase 2
· completed
NCT03402659 — Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
· Phase 2
· completed
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
· Phase 3
· recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
· recruiting
NCT06774443 — Hinting Task for Huntington's Disease
· recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease.
· recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease
· recruiting
Other EIP Pharma Inc trials
Trials by the same sponsor.
NCT06987643 — A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
· Phase 2
· recruiting
NCT06815965 — A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
· Phase 2
· completed
NCT05869669 — RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
· Phase 2
· completed
NCT04001517 — Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
· Phase 2
· completed
NCT03402659 — Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EIP Pharma Inc
Last refreshed: 6 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980938.